Video

Orano Med: Developing Nuclear Medicine for Tomorrow’s Cancer Treatments

Orano Med is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells. With its partners, Orano Med pursues the development of effective therapies to address cancer patients’ needs. Orano Med is the medical subsidiary of the Orano group.

Orano Med Video

Click here to view the latest Orano Med Video

Contact

For more information about Orano Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673